PR is a GTM Lever. Most Healthtech and Medtech Companies Treat It Like a Comms Function.

We have had more conversations with medtech and healthtech founders and commercial leaders than I can count. They have a strong product. A real customer base. Outcomes data that would make a health system executive stop scrolling. And a PR program that activates twice a year, once for a funding round and once for a feature launch.

When we ask how PR connects to their go-to-market motion, the answer is usually some version of “it supports brand awareness.” Then the conversation moves on to pipeline, sales hiring, and campaign spend.

That is the wrong frame. And it is costing companies more than they realize. Outcomes Rocket's PR's Authority Moment: 2026 Benchmark on AI, Visibility & Revenue report confirms the pattern. Only 14.4% of organizations prioritize direct GTM or sales support, and just 6.1% repurpose earned media into sales enablement assets. The function sits adjacent to revenue, rarely inside it.

PR in healthcare is not just a reputation function or a communications checkbox. It is one of the most direct levers a commercial team has for reaching buyers, building credibility before the first conversation, and shortening the distance between awareness and pipeline.

The channels that matter are specific. A CMO reads Modern Healthcare and NEJM Catalyst. A CFO follows Becker's Healthcare. A VP of Clinical Informatics listens to health IT podcasts. A health system CEO reads STAT and Health Affairs. Each shares one quality: they are trusted precisely because they are not controlled by vendors. The credibility comes from an editor or host deciding the perspective was worth amplifying. No ad budget can buy that. No SDR sequence can replicate it.

Nielsen’s Trust in Advertising research shows editorial coverage and peer recommendations are trusted by 60 to 90 percent of consumers, while 55 percent take no action at all after seeing online banner ads. That is not a brand awareness statistic. It is a commercial input.

The play: plan coverage around your ICP, not your news calendar.

Most PR programs are reactive. A funding round, product launch, or partnership prompts a pitch. That is backward from a GTM perspective. Reverse it.

Take your top ten target accounts for the quarter. For each one, answer three questions. What publication or platform does this buyer trust most? What conversation is currently active in that channel: a regulatory shift, a reimbursement change, an operational challenge? What perspective does your team have that contributes something specific to that conversation?

If you can answer all three, build the pitch around that intersection. Make it about what your buyer cares about, in the channel they trust, at the moment the conversation is active. Coverage becomes relevant by design, not by accident.

If you cannot answer one of those questions, you are not close enough to the buyer’s world yet. That gap is worth knowing before you start writing.

The healthtech companies getting the most commercial value from PR share one structural characteristic. Their executives have a genuine point of view on where healthcare is going and why the current approach is falling short. That point of view earns coverage because editors and hosts are looking for perspective, not product announcements. If your leadership team cannot articulate that position in two sentences, your PR program will always default to press releases.

Take this to the office today. Pull your last three earned media placements. For each one, ask: which of your top ten target accounts was this designed to reach? If the answer is “none specifically,” you have a coverage planning problem before you have a measurement problem. The fix starts with the matrix above, not with a bigger PR budget.